Oct 19 2010
Ingenuity® Systems, the leading provider of information solutions for life science researchers, and TransMed Systems, a translational medicine software and services company, today announced an integration between IPA® software and XB Bio-Integration Suite (XB-BIS). Researchers can now easily take pre-clinical and clinical data that is managed and statistically analyzed by XB-BIS, directly into IPA®, which is used by researchers to model, analyze, and explore various types of 'omics data to gain a deeper understanding of complex biological systems.
The software integration supports academic and commercial researchers who are studying how genes affect the way individuals respond to drug treatments. Joint customers will have a clear workflow to analyze pre-clinical and clinical data in the context of signaling and metabolic pathways, networks, and cellular processes available in IPA. This approach helps researchers move rapidly and confidently from hypothesis generation to validation experiments.
Nick Berens, CEO, TransMed Systems, said, "The integration between XB-BIS and IPA will enable physicians, clinicians and researchers to integrate the latest biological content, pathways and molecular networks into their translational medicine and research. These enhanced capabilities will allow for more timely and informed treatment strategies and practices and improve personalized medicine."
Doug Bassett, Ph.D., CSO and CTO, Ingenuity Systems, stated, "Personalized medicine requires the ability to quickly translate large amounts of data into meaningful biological information. We're very pleased that our partnership with TransMed will provide a streamlined platform from which researchers and clinicians will be able to collect and analyze data, link genotypes to phenotypes, identify potential biomarkers, generate powerful and informed hypotheses, and understand the molecular differences between patient populations for improved diagnostics and therapeutics."
AI and predictive medicine: Recent advances